NCT07938866
Genomic Predictors of Response to CAR-T and BiTE Therapies in B-cell Non-Hodgkin Lymphomas
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Number of participants who achieve complete remission (CR) following CAR-T therapy
Timeframe: From enrollment to 360 days after CAR-T/BiTE therapy
Secondary (1)
Number of participants with progression-free survival (PFS) at 1 year
Arms and interventions
Registry Patients
Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL)